{"id":"W3202236569","doi":"10.1158/1078-0432.ccr-21-1181","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Nivolumab; Maximum tolerated dose; Clinical trial; Solid tumor; Immunotherapy; Phases of clinical research; Cytotoxic T cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006166174,0.0002980306,0.001508661,0.000643865,0.0001020554,0.00005763142,0.0004656706,0.0002252654,0.0007845024],"category_scores_gemma":[0.003045335,0.0002203262,0.0001054505,0.002772477,0.001093727,0.0003366988,0.0002137229,0.002168046,0.00002042609],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006127831,"about_ca_system_score_gemma":0.006377688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001685918,"about_ca_topic_score_gemma":0.006611357,"domain_scores_codex":[0.9913185,0.001905386,0.00174336,0.001153465,0.002776607,0.001102702],"domain_scores_gemma":[0.9942938,0.00135917,0.0002930296,0.001076066,0.002414386,0.0005635406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4211534,0.02459661,0.5117179,0.0006555646,0.0001271288,0.001116311,0.0004590781,0.00008540271,0.001770463,0.0000396735,0.0005393014,0.03773921],"study_design_scores_gemma":[0.5910782,0.05006564,0.3415013,0.003725516,0.00004683247,0.00001032217,0.0007842662,0.0008759049,0.01008509,0.00009330082,0.00125142,0.0004822048],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994075,0.0002843715,0.00001529737,0.001743008,0.0001905765,0.003259872,0.00009350176,0.00003080573,0.0003075749],"genre_scores_gemma":[0.9967209,0.001038683,0.0004655826,0.0001961204,0.0002154651,0.0003436547,0.0002290838,0.00009896249,0.0006915359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1702166,"threshold_uncertainty_score":0.9992552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1419866974866878,"score_gpt":0.559179952943152,"score_spread":0.4171932554564642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}